Zydus Partners with CSIR-CDRI to Develop Treatment for CKD-Induced Osteoporosis

Zydus Lifesciences announced on Friday its partnership with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a treatment for osteoporosis caused by chronic kidney disease (CKD).

According to the agreement, Zydus and CDRI will collaborate on preclinical research. Any potential drug candidates resulting from this effort will be developed by Zydus for the Indian and global markets.

As reported by health.economictimes.indiatimes, Pankaj Patel, Chairman of Zydus Lifesciences, emphasized the synergy created by CDRI’s expertise in biomedical research and Zydus’ innovative drug discovery approach. He highlighted that the collaboration aims to explore new treatments for bone metabolism disorders, offering CKD patients effective and affordable therapies to enhance their quality of life.

CKD, which affects more than 10 percent of the global population, leads to a gradual decline in kidney function and can progress to kidney failure.

CSIR-CDRI Director Radha Rangarajan remarked that this partnership, combining the strengths of both organizations and their shared goal of addressing India’s healthcare needs, is a significant step toward innovative drug development. He also pointed out the potential of public-private collaborations to accelerate cutting-edge research in India.

Also Read |  New Obesity Drug Fusion Shows Promise in Animal Studies

As of Friday, Zydus shares were down 0.54 percent, trading at Rs 1,062.60 on the BSE.